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Abstract
Background: Gait is emerging as a powerful diagnostic and prognostic tool, and as a surrogate marker of disease
progression for Parkinson’s disease (PD). Accelerometer-based body worn monitors (BWMs) facilitate the
measurement of gait in clinical environments. Moreover they have the potential to provide a more accurate
reflection of gait in the home during habitual behaviours. Emerging research suggests that measurement of gait
using BWMs is feasible but this has not been investigated in depth. The aims of this study were to explore (i) the
impact of environment and (ii) ambulatory bout (AB) length on gait characteristics for discriminating between
people with PD and age-matched controls.
Methods: Fourteen clinically relevant gait characteristics organised in five domains (pace, variability, rhythm,
asymmetry, postural control) were quantified using laboratory based and free-living data collected over 7 days
using a BWM placed on the lower back in 47 PD participants and 50 controls.
Results: Free-living data showed that both groups walked with decreased pace and increased variability, rhythm
and asymmetry compared to walking in the laboratory setting. Four of the 14 gait characteristics measured in
free-living conditions were significantly different between controls and people with PD compared to two measured
in the laboratory. Between group differences depended on bout length and were more apparent during longer
ABs. ABs ≤ 10s did not discriminate between groups. Medium to long ABs highlighted between-group significant
differences for pace, rhythm and asymmetry. Longer ABs should therefore be taken into account when evaluating
gait characteristics in free-living conditions.
Conclusion: This study provides encouraging results to support the use of a single BWM for free-living gait
evaluation in people with PD with potential for research and clinical application.
Keywords: Parkinson’s disease, Gait, Body worn monitor, Accelerometer, Free-living data, Ambulatory activity
Background
A more efficient healthcare system is required to cope
with increased life expectancy and the growing world
population where ageing related neurological diseases, gait
disorders, and falls risk represent a major challenge and
burden [1]. In this context quantitative measurement of
gait has an important role to play to detect early disease
and to inform disease mechanism and progression, and
optimal management. Until recently, gait assessment has
been limited to specialised laboratory facilities providing
useful information about gait impairment in ageing and
pathology such as Parkinson’s disease (PD) [2–5]. Body
worn monitors (BWMs) [6] now provide a robust and in-
expensive solution for continuous monitoring of ambula-
tory activity in both controlled [7–11] and free-living
environments [3, 4, 12, 13].
In line with developments in gait measurement, frame-
works to characterise gait are being developed which
take a more comprehensive view by expanding the
boundaries of measurement. Gait is conceptualised at
micro level (i.e. spatiotemporal and gait dynamics), and
macro level (i.e. volume, pattern and variability of
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ambulatory activity). Measuring gait in real life reflects
habitual gait performance [14, 15], and is not con-
founded by heightened attention or altered by observer
effect found during laboratory based assessment, even
when naturalistic environments are simulated [16].
BWMs also allow movement to be captured continu-
ously over longer periods of time which is not practical
in a laboratory or clinical setting.
Even though the use of modern BWMs is increasing in
both controlled and free-living environments, this is still
a relatively new field of research where data extraction
and analysis methods are constantly under development
[17]. To date, important established gait characteristics
such as stance time, swing time, and asymmetry gait
characteristics have not yet been quantified in free-living
contexts for people with PD or older adults, while sev-
eral novel frequency based outcomes (although promis-
ing) currently lack a basis from which to interpret their
clinical meaningfulness [2–5].
Quantifying gait characteristics in unsupervised envi-
ronments presents considerable contextualising and
methodological challenges. Despite these challenges, re-
sults from previous work [3–5, 18] have shown the poten-
tial benefits of data collected in unsupervised and
uncontrolled conditions for detecting falls risk in people
with PD and older adults. However, further research is re-
quired to test a more comprehensive range of gait charac-
teristics than what has currently been achieved. Also,
protocols for derivation of gait outcomes differ, making in-
terpretation difficult [19]. For example, some studies
evaluate gait characteristics by recording durations that
range from three days to eight weeks [4, 20–23]. There is
also methodological ambiguity surrounding the optimal
bout length to use for extraction of gait characteristics.
Ambulatory activity is made up of ambulatory bouts (ABs)
of different lengths reflecting the context (home, commu-
nity) and activity the individual is engaged in. It is likely
that context and activity will impact on gait characteristics
making bout length an important consideration. There is
no clear definition of AB and arbitrary values are utilised
across studies where criteria may vary based on number
of steps or length of time [24]. For example, AB lengths
ranging from three steps to longer than 60s have been
used [2, 3, 12, 18, 23, 25, 26], even though it has been
shown that adults tend to walk in short ABs (on average
less than 30s with the highest percentage of ABs lasting
20s or less) [13, 18, 21]. Moreover some studies evaluating
free-living gait characteristics recorded over three days in
people with PD limited analysis to ABs longer than 60s
only, although the authors did not address the reproduci-
bility of laboratory versus free-living outcomes [3–5, 22].
The aims of this study were therefore to: (i) explore
the impact of environment and pathology by analys-
ing differences between people with PD and controls
in the laboratory and free-living environments; (ii) in-
vestigate the impact of bout length on free-living gait
characteristics for discriminating between groups. We
carried out quantitative gait analysis in controlled and
free-living environments using a theoretical model of
gait to inform selection of gait characteristics and ex-
plored the influence of bout length on gait character-
istics to discriminate between groups. We had two a-
priori hypotheses:
i. between-group differences would be more apparent
in free-living conditions than in the laboratory;
ii bout length would impact on free-living gait charac-
teristics for both groups and influence between-
group differences.
Methods
Participants
PD participants and controls were recruited from the Inci-
dence of Cognitive Impairment in Cohorts with Longitu-
dinal Evaluation—GAIT (ICICLE-GAIT) study. This is a
collaborative study with ICICLE-PD, an incident cohort
study (Incidence of Cognitive Impairment in Cohorts with
Longitudinal Evaluation—Parkinson’s disease) conducted
between June 2009 and December 2011 [27, 28].
Participants were excluded if they had a poor com-
mand of English and any neurological (other than
PD), orthopaedic or cardiothoracic conditions that
may have markedly affected their walking or safety
during the testing sessions. In addition, PD partici-
pants had to be diagnosed with idiopathic PD accord-
ing to the UK Parkinson’s Disease Brain Bank criteria
and were excluded if they presented with significant
memory impairment (Mini Mental State Exam
(MMSE) < 24 [29]), dementia with Lewy bodies, drug
induced parkinsonism, ‘vascular’ parkinsonism and
atypical forms of parkinsonism such as progressive
supranuclear palsy, multiple system atrophy, or corti-
cobasal degeneration, according to accepted diagnostic
criteria [30].
Ethics, consent and permissions
Testing took place at the Clinical Ageing Research Unit,
Newcastle University. This study was conducted accord-
ing to the declaration of Helsinki and had ethical ap-
proval from the Newcastle and North Tyneside research
ethics committee. All participants signed an informed
consent form prior to testing.
Demographic and clinical measures
Age and sex were recorded for each participant. The se-
verity of PD motor symptoms was measured using the
Hoehn and Yahr scale [31], which ranges from 0 (no
symptoms) to 5 (wheelchair bound or bedridden if
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unaided) and section III of the modified Movement Dis-
order Society version of the Unified Parkinson’s Disease
Rating Scale (MDS-UPDRS [32]), which ranges from 0
(no motor symptoms) to 132 (severe motor symptoms).
Levodopa equivalent daily dose (LEDD) scores were calcu-
lated according to established methods [33].
Laboratory data collection: equipment and gait protocol
Each participant was asked to wear a single tri-axial
accelerometer-based BWM (Axivity AX3, York, UK;
dimensions: 23.0 × 32.5 × 7.6 mm; weight: 9 g; accur-
acy: 20 parts per million) which has been validated
for its suitability in capturing high-resolution data
Fig. 1 a Example of body worn monitor placement for both the laboratory based and free-living data collection. b Vertical acceleration and
walking bout extraction (signal segments in black) from free-living data. c Example of gait characteristic extraction from walking bouts: detecting
initial contacts (black stars) and final contacts (white circles). The black solid line represents vertical acceleration (av), the dashed line represents the
differentiated with Gaussian CWT of av (avd), and the dotted line represents the differentiated with Gaussian CWT of avd (avdd). d Conceptual model
of gait representing domains and 14 gait characteristics
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akin to human movement [34]. The BWM was lo-
cated on the fifth lumbar vertebra (L5, Fig. 1(a)), at-
tached directly to the skin with double sided tape
(Wig Tape, Natural Image, UK) and covered with
Hypafix (BSN Medical Limited, Hull, UK). The device
was programmed to capture data at 100 Hz (16-bit
resolution) and at a range of ± 8 g [11].
Participants were asked to perform four intermittent
straight line walking trials over a 10 m walkway at
their preferred speed [14, 35, 36]. People with PD
were tested approximately one hour after their medi-
cation intake.
Free-living data collection: protocol
At the end of the laboratory testing session participants
were asked to wear the BWM for one week [20]. The
BWM was attached above L5 with a hydrogel adhesive
(PALStickies, PAL Technologies, Glasgow, UK) and cov-
ered with the Hypafix bandage for extra support. The
BWM was programmed to record continuously for 7
days. Participants were asked to continue their daily ac-
tivities as usual and not to change their routine. Upon
completion of recording, participants removed the de-
vice and posted it back to the researcher as detailed in
previous work [13].
Fig. 2 Summary flowchart of outcomes and methodology used for evaluation of the 14 gait characteristics of the gait model
Table 1 Demographic data.
Characteristic CL (n = 50) Mean (SD) PD (n = 47) Mean (SD) p
Male/female (n) m 27, f 23 m 34, f 13 0.062
Age (years) 69.8 (7.2) 69.1 (8.3) 0.694
MMSE (0 - 30) 28.4 (1.7) 28.3 (2.0) 0.827
MoCA (0 - 30)+ 27.6 (2.4) 26.0 (3.8) 0.016
GDS (0 - 15) 1.0 (1.5) 2.7 (2.7) <0.001
MFI Total fatigue (20 - 100) 34.7 (13.2) 49.9 (18.6) <0.001
ABCs (0 - 100 %) 91.7 (11.0) 80.4 (18.4) 0.001
Hoehn & Yahr stage (n) - HY I 5 -
HY II 39
HY III 3
Levodopa Equivalent Daily Dose - 419.6 (214.0) -
MDS-UPDRS III - 32.0 (10.1) -
Freezing of gait (n, %) - 7 (14.9 %) -
Motor Phenotype (n) - PIGD 18 -
ID 6
TD 23
MMSE mini mental state exam, MoCA montreal cognitive assessment, GDS geriatric depression scale, MFI multidimensional fatigue inventory, ABCs activities
specific balance confidence scale, UPDRS Unified Parkinson’s disease rating scale, PIGD postural instability and gait disorder phenotype, ID indeterminate
phenotype, TD tremor dominant phenotype. p difference between CL and people with PD. In bold significant p values (p < 0.05)
Clinical and demographic characteristics for control participants (CL), and people with Parkinson’s disease (PD). In bold are shown significant p values < 0.05
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Data processing and analysis
Data processing and variable extraction – laboratory
BWM data were downloaded to a computer, segmented
into four different straight line passes using time stamps
and analysed by a bespoke MATLAB® (R2012a) program.
Accelerometer signals were transformed to a horizontal-
vertical coordinate system [37], and filtered with a 4th
order Butterworth filter at 20 Hz [7, 8, 38]. The calcula-
tion of the 14 gait characteristics representative of five
domains (pace, variability, rhythm, asymmetry and
postural control, Fig. 1(d)) is extensively described in
[10, 11]; the same methodology was applied to both the
groups. Briefly: the initial contact (IC, heel strike) and
final contact (FC, toe-off ) events within the gait cycle
were identified from the Gaussian continuous wavelet
transform of the vertical acceleration. ICs and FCs de-
tection allowed the estimation of step, stance and swing
time [11]. The IC events were also used to estimate step
length using the inverted pendulum model [38]. To esti-
mate a value for step velocity we utilised the simple ratio
between step distance (length) and step time [11].
From this it was possible to determine 14 gait character-
istics of the theoretical model of gait which comprise 5
domains (pace, variability, rhythm, asymmetry and
postural control) as detailed elsewhere [10, 11, 36]. To cal-
culate step variability, the standard deviation (SD) from all
steps (left and right combined) was calculated. Asymmetry
was determined as the absolute difference between left
and right steps (alternating) for each walking pass, aver-
aged across all passes [11, 35, 39]. A summarising flow-
chart of this methodology is presented in Fig. 2.
Data processing and variable extraction – free-living data
Once the BWM was received, data were downloaded,
segmented (per calendar day). For each day, individual
ABs were extracted via MATLAB®, where a ‘bout’ was
defined as the continuous length of time spent walking
[13] (Fig. 1(b)). AB were detected applying selective
thresholds on the standard deviation and the magnitude
vector of the triaxial accelerations [40]. The 14 gait char-
acteristics previously described [11] were evaluated from
each of the detected AB (section 2.6.1, Fig. 1(c)).
Data considerations
For the purpose of this study we decided to take a conser-
vative approach and chose a threshold of three steps
(minimum bout length) to define ABs [12, 18, 23, 26],
with no threshold set for the maximum resting period
Table 2 Laboratory based and free-living gait characteristics.
Domain/gait
characteristic
BWM Lab BWM free-living
CL (n = 50) PD (n = 47) p CL (n = 50) PD (n = 47) p
Pace
Step Velocity (m/s) 1.393 ± 0.207 1.254 ± 0.211 0.002 1.097 (0.48) 1.017 (0.426) <0.001
Step Length (m) 0.726 ± 0.095 0.667 ± 0.073 0.001 0.601 (0.183) 0.578 (0.243) <0.001
Swing Time Var (s) 0.018 (0.113) 0.025 (0.103) 0.051 0.147 (0.125) 0.151 (0.134) 0.014
Variability (SD)
Step Velocity Var (m/s) 0.073 (0.301) 0.081 (0.223) 0.253 0.383 (0.494) 0.362 (0.221) 0.070
Step Length Var (m) 0.033 (0.096) 0.039 (0.094) 0.050 0.151 (0.079) 0.152 (0.091) 0.660
Step Time Var (s) 0.019 (0.109) 0.028 (0.085) 0.037 0.175 (0.156) 0.181 (0.179) 0.037
Stance Time Var (s) 0.022 (0.109) 0.029 (0.092) 0.088 0.188 (0.161) 0.196 (0.249) 0.034
Rhythm
Step Time (s) 0.525 ± 0.047 0.539 ± 0.058 0.206 0.593 (0.144) 0.605 (0.318) 0.017
Swing Time (s) 0.371 ± 0.040 0.388 ± 0.055 0.092 0.449 (0.113) 0.458 (0.252) 0.008
Stance Time (s) 0.679 ± 0.061 0.689 ± 0.069 0.450 0.741 (0.166) 0.756 (0.434) 0.035
Asymmetry
Step Time Asy (s) 0.007 (0.140) 0.009 (0.057) 0.268 0.093 (0.086) 0.098 (0.142) 0.116
Swing Time Asy (s) 0.010 (0.126) 0.007 (0.055) 0.473 0.084 (0.064) 0.091 (0.133) 0.013
Stance Time Asy (s) 0.007 (0.140) 0.006 (0.035) 0.665 0.094 (0.086) 0.100 (0.131) 0.097
Postural Control
Step Length Asy (m) 0.007 (0.060) 0.009 (0.086) 0.845 0.081 (0.043) 0.088 (0.070) 0.004
Var Variability, Asy Asymmetry
Values of gait characteristics for controls (CL) and people with Parkinson’s disease (PD) for laboratory based data (BWM Lab) and averaged free-living data (BWM
free-living), values of normal gait characteristics are presented as mean ± standard deviation (SD), non-normal as median (range). Results of the t-test or the
Mann–Whitney U test (for non-normal gait characteristics) analysis between people with PD and CL are reported, in bold are shown p values < 0.01
Del Din et al. Journal of NeuroEngineering and Rehabilitation  (2016) 13:46 Page 5 of 12
Fig. 3 Radar plot illustrating the 14 gait characteristics organised by domain for people with Parkinson’s disease (PD) and controls (CL) evaluated
in the laboratory (Lab). The central dotted line represents CL data, deviation from zero along the axis radiating from the centre of the plot
represents how many standard deviations (range: ±2 SD, z score based on control means and standard deviations) the PD differ from CL.
Asterisks represent significant differences between PD and CL (p values < 0.01)
Fig. 4 Radar plot illustrating the 14 gait characteristics organised by domain for people with Parkinson’s disease (PD) and controls (CL) evaluated
in free-living conditions. The central dotted line represents CL data, deviation from zero along the axis radiating from the centre of the plot
represents how many standard deviations (range: ± 2 SD, z score based on control means and standard deviations) the PD differ from CL.
Asterisks represent significant differences between PD and CL (p values < 0.01)
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between consecutive ABs [41]. Therefore each AB was
considered individually in order to ensure robustness for
the evaluation of the gait characteristics and to avoid
sources of error in step detection, or for the calculation of
variability and asymmetry characteristics (see section
2.6.1).
For consistency with the procedure used in the labora-
tory setting, the gait characteristics were evaluated for
each single AB and then averaged over the 7 days.
Statistical analysis
Statistical analysis was carried out using SPSS v19
(IBM). Normality of data was tested with a Shapiro-Wilk
test. Descriptive statistics were reported as means and
standard deviations (SD), or median and range depend-
ing on the normality of the distributions of gait charac-
teristics. Clinical and demographic characteristics were
described but not used in further analysis.
To test the impact of pathology and environment we
examined between-group differences (controls vs. people
with PD) using parametric t-tests or Mann–Whitney U
tests (if not normally distributed) for each gait character-
istic measured in the laboratory and in free-living condi-
tions, and within-group difference (laboratory vs. free-
living data) using Wilcoxon signed-rank tests. Spearman
rank-order correlations and Mann–Whitney U tests
were used to examine the agreement between laboratory
based and free-living data.
Secondary analysis explored the impact of AB length
on free-living gait characteristics with reference to path-
ology and environment. ABs were grouped depending
on their length (ABs ≤ 10s, 10s < ABs ≤ 20s, 20s < ABs ≤
30s, 30s < ABs ≤ 60s, 60s < ABs ≤ 120 s, ABs > 120 s) and
comparisons of gait characteristics between PD and CL
were performed for each length using independent para-
metric or Mann–Whitney U tests.
We used a threshold of p < 0.01 to guide statistical in-
terpretation. Given the exploratory nature of this study,
we did not correct for multiple comparisons [42, 43].
However, we provide the p value for each comparison so
that the reader may assess the statistical strength of our
findings.
Results
Fifty controls and 47 people with PD were assessed.
Compared to controls, people with PD were age
matched but included proportionally less women (con-
trols: 46 %, PD: 28 %), and presented with lower balance
confidence; poorer cognition; and increased fatigue and
depression (although the depression scores remained
within the normal range). Participants with PD were in
the early stages of the disease with mild motor symp-
toms. Participant demographic, clinical and cognitive de-
scriptors are shown in Table 1.
Impact of environment and pathology
Fourteen gait characteristics were replicated in both la-
boratory and free-living conditions (Table 2). Not sur-
prisingly the impact of environment was significant for
all gait characteristics (p < 0.001). Both groups walked
with decreased pace, increased rhythm, higher variability
and asymmetry in free-living compared to the laboratory
environment (Table 2). Free-living data showed low to
moderate correlations (r ≤ 0.453) with laboratory results
for both groups. In both environments people with PD
walked at a slower pace (with slower and shorter steps),
Fig. 5 Mean number of walking bouts over seven days of recording for different ambulatory bout (AB) lengths (ABs≤ 10s, 10s < ABs≤ 20s,
20s < ABs ≤ 30s, 30s < ABs≤ 60s, 60s < ABs≤ 120 s, ABs > 120 s) for both people with Parkinson’s disease (PD, black) and controls (CL, white)
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Table 3 Impact of bout length on free-living gait characteristics
Domain/gait
characteristic
ABs≤ 10s 10s < ABs ≤ 20s 20s < ABs≤ 30s
CL (n = 50) PD (n = 47) p CL (n = 50) PD (n = 47) p CL (n = 50) PD (n = 47) p
Pace 1663 steps 1603 steps 2196 steps 1926 steps 1517 steps 1181 steps
Step Velocity (m/s) 0.934 (0.374) 0.910 (0.640) 0.145 1.046 ± 0.067 1.010 ± 0.111 0.059 1.082 (0.385) 1.009 (0.569) 0.003
Step Length (m) 0.537 (0.143) 0.528 (0.208) 0.066 0.588 (0.149) 0.570 (0.198) 0.002 0.600 (0.160) 0.587 (0.164) 0.001
Swing Time Var (s) 0.166 ± 0.013 0.172 ± 0.021 0.097 0.156 (0.093) 0.162 (0.097) 0.056 0.152 (0.133) 0.158 (0.097) 0.056
Variability (SD)
Step Velocity Var (m/s) 0.390 (0.172) 0.374 (0.232) 0.196 0.383 (0.212) 0.376 (0.221) 0.479 0.388 (0.347) 0.375 (0.199) 0.511
Step Length Var (m) 0.163 (0.048) 0.160 (0.072) 0.231 0.153 (0.057) 0.154 (0.065) 0.431 0.150 (0.086) 0.154 (0.052) 0.048
Step Time Var (s) 0.204 (0.095) 0.205 (0.138) 0.457 0.186 (0.116) 0.187 (0.155) 0.289 0.181 (0.172) 0.183 (0.155) 0.201
Stance Time Var (s) 0.217 (0.114) 0.219 (0.193) 0.431 0.198 (0.144) 0.201 (0.191) 0.191 0.192 (0.194) 0.195 (0.194) 0.164
Rhythm
Step Time (s) 0.611 (0.106) 0.61 (0.306) 0.639 0.609 (0.121) 0.618 (0.384) 0.220 0.607 (0.140) 0.619 (0.407) 0.054
Swing Time (s) 0.468 (0.090) 0.471 (0.230) 0.436 0.467 (0.103) 0.474 (0.298) 0.201 0.463 (0.105) 0.477 (0.305) 0.033
Stance Time (s) 0.760 (0.159) 0.755 (0.403) 0.891 0.761 (0.186) 0.760 (0.512) 0.488 0.753 (0.193) 0.758 (0.553) 0.130
Asymmetry
Step Time Asy (s) 0.164 (0.123) 0.164 (0.171) 0.639 0.083 (0.135) 0.084 (0.156) 0.751 0.056 (0.103) 0.058 (0.112) 0.402
Swing Time Asy (s) 0.123 (0.080) 0.125 (0.133) 0.316 0.075 (0.116) 0.077 (0.144) 0.164 0.049 (0.082) 0.053 (0.147) 0.151
Stance Time Asy (s) 0.165 (0.116) 0.164 (0.149) 0.702 0.084 (0.131) 0.084 (0.149) 0.398 0.055 (0.108) 0.059 (0.132) 0.217
Postural Control
Step Length Asy (m) 0.125 ± 0.012 0.121 ± 0.018 0.173 0.090 (0.117) 0.088 (0.102) 0.359 0.073 (0.068) 0.069 (0.074) 0.071
30s < ABs≤ 60s 60s < ABs≤ 120 s ABs > 120 s
CL (n = 50) PD (n = 47) p CL (n = 50) PD (n = 47) p CL (n = 50) PD (n = 47) p
Pace 2226 steps 1632 steps 1596 steps 1205 steps 3797 steps 2975 steps
Step Velocity (m/s) 1.103 (0.411) 1.038 (0.422) <0.001 1.110 (0.419) 1.032 (0.472) 0.003 1.137 (1.035) 1.029 (0.686) <0.001
Step Length (m) 0.609 (0.173) 0.593 (0.185) 0.003 0.608 (0.194) 0.590 (0.236) 0.034 0.632 (0.269) 0.581 (0.206) 0.005
Swing Time Var (s) 0.147 (0.138) 0.153 (0.134) 0.029 0.142 (0.127) 0.144 (0.156) 0.279 0.125 (0.174) 0.146 (0.181) 0.014
Variability (SD)
Step Velocity Var (m/s) 0.376 (0.326) 0.369 (0.265) 0.411 0.370 ± 0.051 0.353 ± 0.062 0.153 0.354 (0.559) 0.351 (0.803) 0.573
Step Length Var (m) 0.148 (0.106) 0.150 (0.093) 0.141 0.144 (0.073) 0.146 (0.115) 0.806 0.145 (0.153) 0.150 (0.126) 0.511
Step Time Var (s) 0.174 (0.173) 0.178 (0.178) 0.033 0.170 (0.168) 0.172 (0.219) 0.214 0.151 (0.224) 0.180 (0.233) 0.042
Stance Time Var (s) 0.187 (0.199) 0.190 (0.249) 0.054 0.182 (0.185) 0.187 (0.297) 0.179 0.160 ± 0.047 0.181 ± 0.051 0.042
Rhythm
Step Time (s) 0.600 (0.092) 0.610 (0.333) 0.057 0.591 (0.118) 0.604 (0.292) 0.033 0.576 (0.253) 0.599 (0.570) 0.001
Swing Time (s) 0.457 (0.100) 0.469 (0.259) 0.033 0.443 (0.110) 0.453 (0.191) 0.069 0.425 (0.132) 0.443 (0.403) <0.001
Stance Time (s) 0.750 (0.128) 0.753 (0.448) 0.145 0.742 (0.139) 0.755 (0.341) 0.041 0.723 (0.310) 0.754 (0.666) 0.001
Asymmetry
Step Time Asy (s) 0.041 (0.067) 0.045 (0.068) 0.012 0.029 (0.034) 0.031 (0.078) 0.082 0.019 (0.037) 0.022 (0.17) 0.419
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with increased rhythm and a more variable and asym-
metric walking pattern with respect to controls (Table 2,
Figs. 3 and 4). Between-group differences in gait charac-
teristics were exaggerated in free-living conditions
(Fig. 4). Laboratory based results showed significant
between-group differences for two/14 gait characteristics
(step velocity and step length) representing pace (Table 2,
Fig. 3). This increased to four/14 gait characteristics
comprising pace, rhythm and variability in free-living
conditions (Table 2, Fig. 4).
Impact of bout length and pathology
The majority of ABs were shorter than 10s for both
groups (control: 55 %, PD: 59 %), with only 3 % last-
ing longer than 60s for both the groups. All partici-
pants performed at least two ABs over 120 s (a mean
of 52 for people with PD and 62 for CL), however
these longer bouts represented only 1 % of the total
number of ABs for both groups (Fig. 5). For both
groups pace increased with longer bouts, rhythm
tended to increase for bouts lasting 30s and then de-
creased for longer bouts, variability and asymmetry
decreased with the increase of AB duration, and
asymmetry approached similar values observed in the
laboratory for bouts longer than 120 s (Table 3).
Between-group differences were influenced by bout
length (Table 3, Fig. 6). For the shortest ABs (≤10s)
there were no differences (Fig. 5(a)), for ABs between
10s - 20s (step length) and 20s - 30s (step length and
step velocity) only pace differed between groups. ABs
between 30s - 60s showed that people with PD
walked with significantly slower pace and increased
asymmetry compared to controls (Fig. 6(b)). For ABs
between 60s - 120 s, PD participants demonstrated
slower pace than controls. ABs longer than 120 s
showed that five/14 gait characteristics comprising
pace and rhythm differed between groups (Fig. 6(c)).
Discussion
To our knowledge this is the first study to quantify a
comprehensive range of clinically relevant gait character-
istics in a large cohort of controls and people with PD
(total n = 97) in laboratory and free-living conditions.
We found that free-living conditions heightened
between-group differences. Secondary findings were that
bout length had an impact on gait characteristics and
long ABs were more discriminative of PD-specific gait
impairment than short ABs.
Impact of environment and pathology
Regardless of pathology, compared to laboratory based
data, free-living conditions attenuated gait performance.
Although direct comparison between laboratory based
and totally unsupervised free-living gait characteristics
in people with PD has not been previously reported,
these results support early work by Weiss et al. [3, 22]
and Brodie et al. [23] who found a trend towards higher
variability (frequency [22] or step time [23] measures)
and lower cadence [23] for older adults in free-living
condition compared to laboratory settings. This could be
due to the fact that (a) participants may alter their gait
by increasing their pace and decreasing their rhythm
while under observation in controlled environments [16,
23], and (b) the BWM seems to be a more sensitive tool
(i.e. higher values compared to laboratory reference re-
sults (e.g. instrumented walkway)) in evaluating asym-
metry and variability gait characteristics not only in the
laboratory setting but also in real-life conditions [11].
As expected our findings suggest between-group dif-
ferences in gait characteristics were exaggerated for gait
measured in free-living contexts. Although still unclear,
sensitivity of free-living data to pathology may be ex-
plained partly by the reduction of cognitive (attentional)
input which is required for optimal gait in people with
PD [44, 45], and impaired under dual task conditions
[46]. Free-living gait is naturalistically dual task because
of the distractions, environmental obstacles, and task
complexities that limit attentional compensation; while
conversely attentional control is optimised during
scripted gait tests in the laboratory [16, 47]. Gait mea-
sured in free-living contexts may therefore be a more
sensitive surrogate marker of PD pathology compared
with laboratory based measurements and be superior in
assessing features of the disease such as heightened falls
risk and freezing of gait [3–5].
Table 3 Impact of bout length on free-living gait characteristics (Continued)
Swing Time Asy (s) 0.036 (0.055) 0.041 (0.072) 0.001 0.026 (0.033) 0.029 (0.059) 0.166 0.018 (0.050) 0.019 (0.127) 0.525
Stance Time Asy (s) 0.041 (0.067) 0.045 (0.071) 0.009 0.028 (0.041) 0.029 (0.043) 0.065 0.019 (0.040) 0.020 (0.211) 0.453
Postural Control
Step Length Asy (m) 0.055 (0.064) 0.055 (0.073) 0.554 0.036 (0.047) 0.036 (0.058) 0.868 0.020 (0.069) 0.024 (0.766) 0.073
Var variability, Asy asymmetry, steps steps per day
Values of gait characteristics for controls (CL) and people with Parkinson’s disease (PD) derived from free-living data grouped by ambulatory bout (AB) lengths
(ABs ≤ 10s, 10s < ABs ≤ 20s, 20s < ABs ≤ 30s, 30s < ABs ≤ 60s, 60s < ABs ≤ 120 s, ABs > 120 s), values of normal gait characteristics are presented as mean ± standard
deviation (SD), non-normal as median (range). Average number of steps per day (steps) taken into account for each AB length are presented for both the groups. Results
of the t-test or the Mann–Whitney U test (for non-normal gait characteristics) analysis between people with PD and CL are reported, in bold are shown p values < 0.01
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Impact of bout length and pathology
In free-living conditions both groups performed a
large number of very short ABs (ABs ≤ 10s) rather
than prolonged ABs [18, 21, 48] most likely reflecting
habitual behaviours and moving in a constrained en-
vironment such as a house. Consistent with our hy-
pothesis, gait characteristics of people with PD and
controls changed with respect to bout length and ap-
proximated laboratory values for prolonged ABs (>
120 s) where the time was closer to laboratory testing
protocol. This suggests that gait performance depends
on AB length, moreover gait characteristics and the
impact of pathology vary as a function of AB length.
Indeed specifically gait impairment in people with PD
was only evident when looking at longer ABs, with
no group differences observed during very short AB
(≤ 10s). Between-group differences in asymmetry were
found for medium length ABs but not for prolonged
ABs, while variability was more evident for longer
ABs. Being able to detect these changes is important
because asymmetry represents a primary feature of a
number of neurological disorders such as PD [36, 49].
We speculate ABs between 30s and 60s could repre-
sent walking indoors (e.g. home, shopping centre,
etc.) where increased change of directions, turning,
dual tasking, and the environment itself could affect
the asymmetry of walking, while prolonged ABs (>
120 s) could correspond to walking outdoors (e.g.
park) so that a regular steady state is more likely to
be achieved. These results suggest that gait measured
in the free-living context sensitises measurement of
pathology reflecting the heightened control challenges
and limited compensatory adaptability.
Implications for free-living data analysis
Results from this study have important implications
for analysis of gait in free-living data. Very short ABs
(ABs ≤ 10s) did not discriminate for pathology in this
instance, suggesting that a minimum of 10s is re-
quired to detect changes in mean and asymmetry gait
characteristics in people with PD. Only bouts of
medium length (30s < ABs ≤ 60s) were able to detect
between-group differences for asymmetry. Moreover
only 3 % of the walking bouts were greater than 60s.
Fig. 6 Radar plot illustrating the 14 gait characteristics organised by
domain for people with Parkinson’s disease (PD) and controls (CL)
evaluated in free-living conditions for ambulatory bouts (ABs)≤ 10s
(panel (a)), 30s < ABs≤ 60s (panel (b)), and ABs > 120 s (panel (c)).
The central dotted line represents CL data, deviation from zero along
the axis radiating from the centre of the plot represent how many
standard deviations (range: ± 2 SD, z score based for each bout
length on control means and standard deviations) the PD differ from
CL. Asterisks represent significant differences between PD and CL
(p values < 0.01)
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Therefore when considering free-living data it is es-
sential to take into account ABs longer than 10s be-
cause ABs longer than 60s represent only a partial
picture of gait performance.
Limitations
This study informs understanding of the effect of bout
length on outcomes, however further work is required
to identify the merits in merging short ABs to provide
more meaningful data [41].
We used pooled intermittent walks collected in the lab
which can be comparable in duration to short-medium
ABs (10s - 30s) collected in free-living environments, in
the future longer walks (e.g. two minute walks) collected
in the laboratory may be useful for comparing longer
ABs (60-120 s).
Discriminating purposeful from non-purposeful walk-
ing bouts in constrained environments such as a home
is challenging, and requires greater consideration.
This study did not set out to provide an interpret-
ation of the data by revealing the context in which
gait was performed. However, moving forward this
will be important. Use of simultaneous video record-
ing may be a solution although privacy issues then
become evident. Moreover the effect of medication
intake on fluctuations of gait in people with PD needs
to be investigated and on/off periods will likely have
an impact on gait characteristics. Lastly, despite
choosing a stringent p value of 0.01, we acknowledge
this does not completely mitigate the inflation of type
I error introduced by multiple comparisons. We feel
this approach is justified given the exploratory nature
of the work as we did not want to unduly increase
the risk of type II statistical error [42, 43]. Although
the resulting findings will be important for future hy-
pothesis generation, as noted they may vary with re-
spect to the choice of correcting for multiple
comparisons. Therefore, we recommend caution when
applying our findings until they are replicated. To
help the reader interpret the strength of the findings,
we have included the full p values in Tables 2 and 3.
Conclusions
In conclusion this study supports the use of a single
BWM to quantify clinically relevant, pathology-sensitive
gait characteristics in free-living environments. Results
from this study provide a platform for future research to
adopt a broader application of accelerometry data that
will inform our understanding of gait in naturalistic en-
vironments, and the features associated with that
performance.
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